Factors predicting HER-2/neu overexpression in primary operable breast cancers (n = 1362): univariate analysis
| HER-2/neu expression* | Odds ratio† | p Value | ||
|---|---|---|---|---|
| Negative | Positive | |||
| Data are number of patients (%). | ||||
| *HER-2/neu was defined as negative when the DAKO score was 0 or 1+, and positive when 2+ or 3+; †odds ratio adjusted for all variables in table; ‡ER and PR were defined as negative when the H score was ⩽50, and positive when 51–300. | ||||
| ER, oestrogen receptor; PR, progesterone receptor. | ||||
| ER status‡ | ||||
| Negative | 168 (65.1%) | 90 (34.9%) | 3.38 | <0.001 |
| Positive | 953 (86.3%) | 151 (13.7%) | 1 | |
| PR status‡ | ||||
| Negative | 355 (72.7%) | 133 (27.3%) | 2.66 | <0.001 |
| Positive | 766 (87.6%) | 108 (12.4%) | 1 | |
| Tumour grade | ||||
| 1–2 | 741 (89.5%) | 87 (10.5%) | 1 | <0.001 |
| 3 | 380 (71.2%) | 154 (28.8%) | 3.45 | |
| Tumour size | ||||
| ⩽20 mm | 600 (83.2%) | 121 (16.8%) | 1 | 0.349 |
| >20 mm | 521 (81.3%) | 120 (18.7%) | 1.14 | |
| Lymph node | ||||
| Negative | 738 (83.9%) | 142 (16.1%) | 1 | 0.042 |
| Positive | 383 (79.5%) | 99 (20.5%) | 1.34 | |
| Age | ||||
| ⩽50 years | 346 (80.7%) | 83 (19.3%) | 1.18 | 0.278 |
| >50 years | 775 (83.1%) | 158 (16.9%) | 1 | |